The green list includes active pharmaceutical ingredients (APIs) in the GLP-1 drugs that have been inspected by the FDA and are determined to be in compliance with FDA standards
10.3389/fendo.2021.721135 Summary Keywords lymphedema, GLP-1R agonists, GLP-1R agonist, GLP-1RAs, cancer-related lymphedema, Ozempic, semaglutide, liraglutide Citation Brown S, Tadros AB, Montagna G, Bell T, Crowley F, Gallagher EJ and Dayan JH (2024) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
Listen to the full episode of the Live & Well podcast on Spotify and Apple Podcasts .
The role of ferroptosis in cancer development and treatment response
The Iranian version of 12-item Short Form Health Survey (SF-12): factor structure, internal consistency and construct validity